You just read:

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukaemia

News provided by

Astellas

15 Jun, 2015, 12:51 BST